Skip to content
Dr. Grey AI

Peptide

AOD-9604

AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176-191) developed for weight loss. DEVELOPMENT TERMINATED in 2007 after Phase 2b trials showed modest, inconsistent results. C-grade for small weight loss (~2kg over 12 weeks). Despite being abandoned by its developers, it's sold in gray market peptide circles. BANNED by WADA. Not FDA-approved for any use. Animal studies showed better results than human trials.

Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.

Best evidence
Grade C
Conditions studied
2
Outcomes
4
Graded outcomes
0031

Evidence by condition

  • Strong
  • Moderate
  • Limited
  • Very limited

2 conditions

Weight Management

Weight Management: outcomes studied for AOD-9604
GradeOutcomeEffectSizeStudiesPeopleStudies list
Body Weight Reduction

2.8 kg vs 0.8 kg placebo at 12 weeks (1mg dose); inconsistent across doses

Improves (the measure goes down)Small effect8 studies925 people

Studies that measured body weight reduction

Metabolic Health

Metabolic Health: outcomes studied for AOD-9604
GradeOutcomeEffectSizeStudiesPeopleStudies list
Fat Mass Reduction (Animal)

>50% reduction in weight gain in obese mice

Improves (the measure goes down)Large effect7 studies160 people

Studies that measured fat mass reduction (animal)

Insulin Sensitivity

No adverse effect on insulin sensitivity

NoneNo effect7 studies120 people

Studies that measured insulin sensitivity

Cholesterol Profile

Small improvement

Improves (the measure goes down)Small effect7 studies300 people

Studies that measured cholesterol profile

Key findings

  • Body Weight ReductionImproves (the measure goes down)
  • Fat Mass Reduction (Animal)Metabolic HealthImproves (the measure goes down)
  • Insulin SensitivityMetabolic Health

Safety notes in the studies

  • No adverse effect on insulin sensitivity

Studies cited

8 studies from PubMed

  1. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis modelJ Orthop Res, 2015 · PMID 26275694
  2. Detection and in vitro metabolism of AOD9604Rapid Commun Mass Spectrom, 2014 · PMID 25208511
  3. A double-blind placebo-controlled clinical trial of a novel lipolytic agent AOD9604 in obese individualsInt J Obes, 2006 · PMID 16306460
  4. Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology, 2005 · PMID 15834452
  5. Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology, 2003 · PMID 14571286
  6. Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology, 2003 · PMID 14685303
  7. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out miceEndocrinology, 2001 · PMID 11713213
  8. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormoneHorm Res, 2000 · PMID 11146367